转移性黑色素瘤中的爆发性鳞状细胞癌：免疫治疗的意外后果。 - Suppr

Suppr

超能文献

Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapy.

作者信息

Haraszti Samantha, Polly Samantha, Ezaldein Harib H, Rothbaum Robert, Delost Gregory R, Beveridge Mara

机构信息

Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.

Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

出版信息

JAAD Case Rep. 2019 Jun 8;5(6):514-517. doi: 10.1016/j.jdcr.2019.03.014. eCollection 2019 Jun.

DOI:10.1016/j.jdcr.2019.03.014

PMID:31205993

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6558268/

Abstract

摘要

相似文献

Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapy.转移性黑色素瘤中的爆发性鳞状细胞癌：免疫治疗的意外后果。

JAAD Case Rep. 2019 Jun 8;5(6):514-517. doi: 10.1016/j.jdcr.2019.03.014. eCollection 2019 Jun.

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.用于治疗皮肤鳞状细胞癌的免疫疗法。

Front Oncol. 2021 Aug 26;11:733917. doi: 10.3389/fonc.2021.733917. eCollection 2021.

Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab.在转移性皮肤鳞状细胞癌对西米普利单抗程序性细胞死亡蛋白1阻断完全缓解期间，同时发生高分期皮肤鳞状细胞癌。

JAAD Case Rep. 2021 Oct 20;18:23-25. doi: 10.1016/j.jdcr.2021.10.009. eCollection 2021 Dec.

Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.帕博丽珠单抗联合低分割放射治疗晚期不可切除皮肤鳞状细胞癌。

Eur J Dermatol. 2019 Dec 1;29(6):636-640. doi: 10.1684/ejd.2019.3671.

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.异基因造血细胞移植治疗蕈样肉芽肿后皮肤鳞状细胞癌对免疫检查点抑制的快速和持续反应。

J Immunother Cancer. 2019 Dec 4;7(1):338. doi: 10.1186/s40425-019-0801-z.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.

Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.接受帕博利珠单抗和咪喹莫特联合治疗的患者发生鳞状细胞癌爆发。

J Dermatol. 2019 Dec;46(12):1202-1204. doi: 10.1111/1346-8138.15101. Epub 2019 Oct 9.

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.抗 PD-1 单克隆抗体 REGN2810 对转移性基底细胞癌和皮肤鳞状细胞癌的疗效。

J Immunother Cancer. 2016 Nov 15;4:70. doi: 10.1186/s40425-016-0176-3. eCollection 2016.

Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma.程序性细胞死亡蛋白1抑制与放射治疗同时进行可使晚期皮肤鳞状细胞癌完全缓解。

JAAD Case Rep. 2019 Aug 29;5(9):763-766. doi: 10.1016/j.jdcr.2019.06.026. eCollection 2019 Sep.

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.程序性细胞死亡蛋白1或联合程序性死亡蛋白1/细胞毒性T淋巴细胞相关抗原4抑制治疗转移性葡萄膜黑色素瘤的预后因素及结局

Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.

引用本文的文献

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge.病例报告：PD-1抑制剂治疗下伴有真菌合并感染的免疫相关爆发性角化棘皮瘤：诊断和治疗挑战

Front Pharmacol. 2025 Aug 13;16:1619450. doi: 10.3389/fphar.2025.1619450. eCollection 2025.

Paradoxical Emergence of Cutaneous Squamous Cell Carcinoma During Pembrolizumab Treatment for Non-muscle Invasive Bladder Cancer and Subsequent Successful Therapeutic Adjustments.帕博利珠单抗治疗非肌层浸润性膀胱癌期间皮肤鳞状细胞癌的矛盾性出现及后续成功的治疗调整

Cureus. 2025 Mar 9;17(3):e80293. doi: 10.7759/cureus.80293. eCollection 2025 Mar.

Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).非黑色素瘤皮肤癌（NMSC）中的肿瘤微环境免疫检查点和细胞景观。

Cells. 2024 Sep 26;13(19):1615. doi: 10.3390/cells13191615.

To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma.治疗还是不治疗：程序性死亡受体1配体（PD-L1）抑制剂诱发的角化棘皮瘤和鳞状细胞癌

Arch Dermatol Res. 2023 May;315(4):903-915. doi: 10.1007/s00403-022-02468-3. Epub 2022 Nov 17.

Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer.综述：PD-L1 作为治疗和预防角化细胞皮肤癌的新兴靶点。

Mol Carcinog. 2023 Jan;62(1):52-61. doi: 10.1002/mc.23464. Epub 2022 Sep 19.

Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein-1 blockade.程序性细胞死亡蛋白1阻断后爆发性皮肤鳞状细胞癌的形成。

JAAD Case Rep. 2020 Apr 29;6(5):390-393. doi: 10.1016/j.jdcr.2020.02.024. eCollection 2020 May.

本文引用的文献

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.与帕博利珠单抗治疗相关的爆发性角化棘皮瘤

JAMA Dermatol. 2017 Jul 1;153(7):694-697. doi: 10.1001/jamadermatol.2017.0989.

JAAD Case Rep. 2017 Apr 14;3(3):208-211. doi: 10.1016/j.jdcr.2017.02.015. eCollection 2017 May.

Development of bullous pemphigoid during nivolumab therapy.纳武单抗治疗期间大疱性类天疱疮的发生

JAAD Case Rep. 2016 Dec 3;2(6):442-444. doi: 10.1016/j.jdcr.2016.05.009. eCollection 2016 Nov.

Pembrolizumab-associated sarcoidosis.帕博利珠单抗相关的结节病。

JAAD Case Rep. 2016 Jul 27;2(4):290-3. doi: 10.1016/j.jdcr.2016.06.004. eCollection 2016 Jul.

JAAD Case Rep. 2016 Jul 14;2(3):264-8. doi: 10.1016/j.jdcr.2016.05.002. eCollection 2016 May.

Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.帕博利珠单抗治疗转移性黑色素瘤期间出现的反向银屑病样皮疹。

JAMA Dermatol. 2016 May 1;152(5):590-2. doi: 10.1001/jamadermatol.2015.5210.

Toll-like receptor 9 mediates invasion and predicts prognosis in squamous cell carcinoma of the mobile tongue.Toll样受体9介导舌活动部鳞状细胞癌的侵袭并预测其预后。

J Oral Pathol Med. 2015 Sep;44(8):571-7. doi: 10.1111/jop.12272. Epub 2014 Oct 23.

Toll-like receptors and skin cancer.Toll样受体与皮肤癌。

Front Immunol. 2014 Mar 31;5:135. doi: 10.3389/fimmu.2014.00135. eCollection 2014.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验